Display options
Cite
Paris LP, Johnson CH, Aguilar E, et al. Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. Metabolomics. 2015;12:15doi: 10.1007/s11306-015-0877-5.
Paris, L. P., Johnson, C. H., Aguilar, E., Usui, Y., Cho, K., Hoang, L. T., Feitelberg, D., Benton, H. P., Westenskow, P. D., Kurihara, T., Trombley, J., Tsubota, K., Ueda, S., Wakabayashi, Y., Patti, G. J., Ivanisevic, J., Siuzdak, G., & Friedlander, M. (2016). Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. Metabolomics : Official journal of the Metabolomic Society, 1215. https://doi.org/10.1007/s11306-015-0877-5
Paris, Liliana P, et al. "Global metabolomics reveals metabolic dysregulation in ischemic retinopathy." Metabolomics : Official journal of the Metabolomic Society vol. 12 (2016): 15. doi: https://doi.org/10.1007/s11306-015-0877-5
Paris LP, Johnson CH, Aguilar E, Usui Y, Cho K, Hoang LT, Feitelberg D, Benton HP, Westenskow PD, Kurihara T, Trombley J, Tsubota K, Ueda S, Wakabayashi Y, Patti GJ, Ivanisevic J, Siuzdak G, Friedlander M. Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. Metabolomics. 2016;12:15. doi: 10.1007/s11306-015-0877-5. Epub 2015 Nov 18. PMID: 26617478; PMCID: PMC4651979.
Copy Download .nbib Format: NLM
Share it on

Metabolomics. 2016;12:15. doi: 10.1007/s11306-015-0877-5. Epub 2015 Nov 18.

Global metabolomics reveals metabolic dysregulation in ischemic retinopathy.

Metabolomics : Official journal of the Metabolomic Society

Liliana P Paris, Caroline H Johnson, Edith Aguilar, Yoshihiko Usui, Kevin Cho, Lihn T Hoang, Daniel Feitelberg, H Paul Benton, Peter D Westenskow, Toshihide Kurihara, Jennifer Trombley, Kinya Tsubota, Shunichiro Ueda, Yoshihiro Wakabayashi, Gary J Patti, Julijana Ivanisevic, Gary Siuzdak, Martin Friedlander

Affiliations

  1. Department of Cell and Molecular Biology, The Scripps Research Institute, MB 28, 10550 North Torrey Pines Road, La Jolla, CA 92037 USA.
  2. Scripps Center for Metabolomics and Mass Spectrometry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 USA.
  3. Department of Ophthalmology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023 Japan.
  4. Departments of Chemistry, Genetics, and Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
  5. The Lowy Medical Research Institute, 3030 N. Torrey Pines Court, La Jolla, CA 92037 USA.

PMID: 26617478 PMCID: PMC4651979 DOI: 10.1007/s11306-015-0877-5

Abstract

Proliferative diabetic retinopathy (PDR) is the most severe form of diabetic retinopathy and, along with diabetic macular edema, is responsible for the majority of blindness in adults below the age of 65. Therapeutic strategies for PDR are ineffective at curtailing disease progression in all cases; however a deeper understanding of the ocular metabolic landscape in PDR through metabolomic analysis may offer new therapeutic targets. Here, global and targeted mass spectrometry-based metabolomics were used to investigate metabolism. Initial analyses on vitreous humor from patients with PDR (n = 9) and non-diabetic controls (n = 11) revealed an increase of arginine and acylcarnitine metabolism in PDR. The oxygen-induced-retinopathy (OIR) mouse model, which exhibits comparable pathological manifestations to human PDR, revealed similar increases of arginine and other metabolites in the urea cycle, as well as downregulation of purine metabolism. We validated our findings by targeted multiple reaction monitoring and through the analysis of a second set of patient samples [PDR (n = 11) and non-diabetic controls (n = 20)]. These results confirmed a predominant and consistent increase in proline in both the OIR mouse model and vitreous samples from patients with PDR, suggesting that over activity in the arginine-to-proline pathway could be used as a therapeutic target in diabetic retinopathy.

Keywords: Arginine metabolism; Pathway enrichment analysis; Proliferative diabetic retinopathy; Untargeted metabolomics

References

  1. PLoS One. 2011;6(7):e22460 - PubMed
  2. Lancet Diabetes Endocrinol. 2014 Jan;2(1):65-75 - PubMed
  3. Cell Death Dis. 2014 Feb 20;5:e1075 - PubMed
  4. Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2813-26 - PubMed
  5. Indian J Ophthalmol. 2012 Sep-Oct;60(5):428-31 - PubMed
  6. Curr Diab Rep. 2012 Aug;12(4):346-54 - PubMed
  7. Dis Model Mech. 2012 Jul;5(4):444-56 - PubMed
  8. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 - PubMed
  9. Retina. 2014 Jun;34(6):1199-207 - PubMed
  10. Nat Chem Biol. 2012 Jan 22;8(3):232-4 - PubMed
  11. J Neurosci. 2006 Mar 15;26(11):2862-70 - PubMed
  12. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 - PubMed
  13. Prog Retin Eye Res. 2006 Jul;25(4):397-424 - PubMed
  14. Curr Drug Saf. 2014;9(2):156-8 - PubMed
  15. Front Immunol. 2013 Jul 03;4:173 - PubMed
  16. Anal Chem. 2013 Jul 16;85(14):6876-84 - PubMed
  17. Diabetes Obes Metab. 2015 Mar;17(3):219-30 - PubMed
  18. Prog Retin Eye Res. 2013 Sep;36:260-80 - PubMed
  19. Anal Chem. 2012 Jun 5;84(11):5035-9 - PubMed
  20. Diabetes Care. 2014 Apr;37(4):900-5 - PubMed
  21. Anal Chem. 2013 Jan 15;85(2):798-804 - PubMed
  22. Nucleic Acids Res. 2009 Jul;37(Web Server issue):W652-60 - PubMed
  23. Am J Ophthalmol. 1999 Feb;127(2):137-41 - PubMed

Publication Types

Grant support